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ABSTRACT

Objective: The objective of this selective EBM review is to determine whether or not
tildrakizumab monotherapy is effective in treating moderate to severe plaque psoriasis.
Study Design: Systemic review of three randomized placebo controlled clinical trials published
in 2015 and 2017.
Data Sources: Three randomized controlled trials published in peer-reviewed journals comparing
the effects of IV or subcutaneous tildrakizumab to a visually matched placebo for the treatment
of moderate to severe plaque psoriasis. Data sources were found using the PubMed database.
Outcomes Measured: The reduction of psoriatic lesions following treatment was measured using
the Psoriasis Area and Severity Index 75 (PASI 75) through visual evaluation of patients by
investigators.
Results: All three studies demonstrated a reduction in psoriatic lesions with the use of
tildrakizumab. PASI 75 measured at week 12 or 16 showed an approximate 60% absolute benefit
increase with tildrakizumab versus visually matched placebo. This resulted in a NNT of 2 for all
studies.
Conclusions: All three studies illustrated that tildrakizumab is effective as monotherapy for
moderate to severe plaque psoriasis in adults. While this is true, study sample sizes were
relatively small and patient demographics were not representative to the general population.
Further studies are needed to compare tildrakizumab to other biological medications that are
more widely used.
Keywords: tildrakizumab, psoriasis
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INTRODUCTION
Psoriasis is a chronic, inflammatory, hyper-proliferative dermatologic condition that is
caused by genetic and/or environmental irritants.1 There are many different forms of psoriasis
with plaque psoriasis being the most prevalent, affecting about 90% of psoriasis patients.2 Plaque
psoriasis is characterized by well-demarcated, erythematous plaques with a white-silvery scale.
The lesions predominately occur on the scalp, elbows, knees, palms, soles, and nails. Depending
on the location and extent of the disease, psoriasis may make it difficult for a patient to perform
daily tasks or may lead to insecurities regarding their physical appearance.
In addition to the evident rash and scaling of psoriasis, the condition may also impart a
financial burden on the patient due to the cost of medications and office visits. While there has
not been an estimate released in the recent years, a small US study performed in 2013 with 3,000
participants found that patients with moderate to severe psoriasis and/or psoriatic arthritis spent
approximately $20,000 annually on pharmaceutical and associated medical costs.3 Another study
released in 2008 estimated that the annual economic burden of psoriasis in the US was $11.25
billion.4 Little is known of the medical utilization for psoriasis, but a study published in 1996
estimated an average of 1.5 million visits to physician per year for psoriasis.5 Psoriasis is
believed to affect approximately 2% of the world’s population and occurs in most racial groups,
affecting males and females equally.2 The prevalence and detrimental effects of psoriasis on
patients make it necessary for providers to understand the condition and properly treat it.
While the exact cause of psoriasis is unknown, it is known that there is a strong genetic
component, and that environmental and behavioral factors play a role. It is also known that
psoriasis is a complex immune-mediated inflammatory disorder which causes alterations in both
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the adaptive and innate immune systems. These immune cascades lead to the release of cytokines
and ultimately keratinocyte hyperplasia in affected areas.
Conventional treatments for the local skin thickening caused by psoriasis include
emollients, topical glucocorticoids, vitamin D analogs, topical retinoids, tar shampoo, and
anthralin. Phototherapy (UV, NB-UVB) may also be used when topical agents are not sufficient.
Severe psoriasis may require the use of systemic medications such as methotrexate, oral
retinoids, biologics, or immunosuppressants.
The above treatments are all effective in the treatment of psoriasis. However, each patient
reacts differently to medications and the biologic tildrakizumab may prove to be more effective
or have less side effects than other options for certain patients. Tildrakizumab is a monoclonal
antibody that binds to the IL-23p19 subunit which eventually pairs with the IL-12p40 subunit.6
Both of these subunits are overexpressed in psoriasis and together form the heterodimeric
cytokine IL-23.6 By targeting both subunits, and ultimately more of IL-23, researchers are
hoping to more effectively treat psoriasis patients.6
OBJECTIVE
The objective of this selective EBM review is to determine whether or not tildrakizumab
monotherapy is effective in treating moderate to severe plaque psoriasis.
METHODS
All studies included in this selective EBM review were written in English and published
in peer-reviewed journals obtained from PubMed. The keywords used to search these articles
included “psoriasis” and “tildrakizumab”. Studies were selected by this author based on their
relevance to the clinical question and their inclusion of patient-oriented evidence that matters
(POEMs). The inclusion criteria used for this review were randomized clinical trials (RCTs)
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published after 2008 that discussed the efficacy of tildrakizumab as monotherapy for adults with
plaque psoriasis and evaluated the POEM of interest. Exclusion criteria included studies prior to
2008, studies with subjects under 18 years of age, studies that evaluated tildrakizumab’s efficacy
with other therapies, and studies that did not assess the POEM of interest.
Three placebo-controlled RCTs with specific populations, interventions, comparisons,
and outcomes were selected. All studies focused on adult patients over the age of 18 with
moderate to severe plaque psoriasis. The intervention with tildrakizumab through subcutaneous
or IV was administered and compared to a visually matched placebo. These results were
measured using the Psoriasis Area and Severity Index 75 (PASI 75) to objectively record the
reduction of psoriatic lesions following the intervention. PASI is an internationally utilized scale
to rate the severity of psoriasis through its distribution, redness, thickness, and scale. PASI 75 is
when a 75% reduction of psoriasis is seen in an individual from the beginning to the end of the
time period of the trial.
Demographics and characteristics of included studies are outline in Table 1. The
statistical significance of the outcomes measured were determined using relative benefit increase
(RBI), absolute benefit increase (ABI), numbers needed to treat (NNT), number needed to harm
(NNH), and p-value. Outcomes were considered statistically significant if the p-value was ≤ to
0.05.
OUTCOMES MEASURED
All three studies measured the reduction of psoriatic lesions using the Psoriasis Area and
Severity Index 75 (PASI 75). This was done by investigators who visually evaluated each patient
and objectively determined if 75% or more of the psoriasis lesions had cleared from baseline
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after a given time period. These findings were compared to placebo at named time periods for
the respective studies.
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TABLE 1: Demographics and characteristics of included studies
Study

Type

#Pts

Age
(yrs)
1865

Inclusion

Exclusion

W/D

Interventions

Kopp,
2015
(1)

RCT

77

-Healthy adult  18
-Stable diagnosis
-BSA 10% and PASI
12
-On therapy: BSA
10% and PASI 10

12

-Safety
-Efficacy of
IV
tildrakizumab
at 10 mg kg-1

355

1882

-Healthy adult  18
-Diagnosis of
psoriasis > 6 months
- BSA 10% and
PASI 12
-PGA of moderate,
marked, or severe at
baseline

16

-Subcutaneous
injection of
tildrakizumab
at 100 mg

772

1882

-Healthy adult  18
with mod/severe
psoriasis
- BSA 10% and
PASI 12
- PGA  3
-Not pregnant and
abstain from sex or
coverage with
contraception

-Recent psoriasis tx:
topicals in week,
phototherapy in 4
weeks, monoclonal
antibodies in 3
months
-Contraindications
for biologic use
- All subjects were
otherwise healthy
(see Methods of
study for details)
-Contraindication
for biologic use
-Recent abx,
concurrent steroids,
any cancer
-Prior use  2 TNF without efficacy
-Uncontrolled
arrhythmias, HTN,
DM, or cardiac
revascularization
within 6 months of
screening
-Contraindication
for biologic use
-Recent abx
-Live vaccination
within 1 month
-HIV, Hep B/C
-Prior malignancy
excluding minor
skin or CIS of cervix
s/p treatment
-Admission for
cardiovascular
event, illness, or
surgery within 6
months
-Uncontrolled HTN,
DM
-Prior use of
tildrakizumab or IL
23/17 inhibitors or
etanercept

Papp,
2015
(2)

RCT

Reich,
2017
(3)

RCT

28

-Subcutaneous
injection of
tildrakizumab
at 100 mg
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RESULTS
Kopp et al.6 conducted a 3-part, rising dosage, double-blind, phase I RCT to evaluate the
clinical activity, pharmacokinetics, safety, and efficacy of tildrakizumab in subjects with
moderate to severe plaque psoriasis. In part 1, patients were randomized to receive IV placebo,
or IV tildrakizumab at 0.1, 0.5, 3, 10 mg kg-1 on days 0, 56, and 84. IV medication/placebo were
administered over 1 hour. In part 2, after favorable outcomes and limited side effects were seen
during part 1, the lower dosages were eliminated and subjects were randomized to receive IV
placebo, IV tildrakizumab 3 or 10 mg kg-1 on days 1, 28 and 36. Part 3 was added to explore the
efficacy seen at lower dosages during part 1. Data were dichotomous with subjects reaching
PASI 75 or not. All subjects were followed with intention to treat analysis with the exception of
3 subjects who did not return after enrollment.
A total of 77 subjects enrolled with 65 subjects completing the study. Two subjects
discontinued due to side effects, one on 10 mg tildrakizumab due to convulsions, and the other
on placebo due to arthralgia and worsening psoriasis. Another 7 subjects withdrew consent.
Regarding safety and tolerability, 81% of subjects reported no adverse event. The most common
complaints were headache, upper respiratory tract infection, cough, and nasopharyngitis. There
were 11 serious side effects reported by 8 subjects, with convulsions being the only one deemed
possibly related to tildrakizumab.
Endpoint efficacy of treatment was evaluated on week 16 using PASI 75 scores. The
maximum dosage of this phase 1 trial was analyzed. The PASI 75 response at week 16 was 60%
with IV tildrakizumab 10 mg kg-1, compared to 0.0% in the placebo group. This resulted in an
ABI of 60%, and a NNT of 2. None of the subjects receiving placebo reached PASI 75, therefore
RBI was zero. The mean percentage change in baseline PASI 75 extrapolated from Figure 1 in
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the article was approximately 80% for tildrakizumab 10 mg at week 16 for parts 1 and 3
combined.6 No p-value was provided. While the article states, “The mean and 95% confidence
interval (95% CI) was provided for each treatment group as well as the difference between
tildrakizumab and placebo…” no such confidence interval was found.
Papp et al.7 conducted a 3-part, double-blinded, parallel-group, dose-finding phase IIb
RCT to evaluate safety and efficacy of subcutaneous (SQ) tildrakizumab on adult patients with
moderate-severe plaque psoriasis. This study was conducted from November 2010 to June 2012
in 64 sites in the US, Canada, Japan, and Europe. In part 1, subjects were randomized to receive
SQ tildrakizumab (5, 25, 100, 200 mg), or placebo on day 0 and week 4. Subjects in part 1 were
evaluated on week 16. In part 2, all subjects were then re-randomized based on responder status.
They were then either given their current dosage or had their dosage of tildrakizumab increased
to 100 mg or 200 mg. Intervention was administered every 12 weeks until week 52. In part 3,
patients were no longer receiving intervention, but were instead followed for lasting efficacy
until week 72. Considering the preferential re-randomization and lack of a direct control in part
2, only part 1 of the study was evaluated in this review. Data was dichotomous with subjects
reaching PAS1 75 at week 16 or not. All subjects were followed with intention to treat analysis
after a single dose, termed in the article as the “full analysis set”. Subjects who discontinued due
to lack of efficacy, or used prohibited medication were considered to have not met PASI 75 at
week 16. Subjects who discontinued for other reasons were analyzed at their last recorded PASI
value.
A total of 355 subjects were enrolled and randomized, with 353 analyzed in part 1 as 2
subjects were randomized but did not receive treatment. Of the 353, 6 subjects discontinued due
to side effects and 1 subject died. Regarding safety and tolerability in part 1, 65% of subjects
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reported at least one side effect. The incidence of side effects was similar in all experimental
arms including placebo. The most common complaints were headache and nasopharyngitis.
Hypertension was the only dose related side effect affecting 9 out of the 308 subjects receiving
tildrakizumb compared to the 0 out of 45 subjects receiving placebo. The reporting of serious
side effects included 4 subjects in part 1, 14 subjects in part 2, and 5 subjects in part 3. Of these
serious side effects, the ones that may have been caused by tildrakizumab included: bacterial
arthritis, lymphedema, melanoma, stroke, epiglottitis, and infection of the knee. A 63 year-old
gentleman with a history of alcohol abuse died of unknown causes during part 1 of the study. He
was dosed at 100 mg tildrakizumab. Autopsy was inconclusive, but a blood alcohol level of
0.275% was noted.
Endpoint efficacy of treatment was evaluated on week 16 using PASI 75 scores. The
PASI 75 response at week 16 was 66% for SQ tildrakizumb 100 mg. The PASI 75 for placebo
was 4%. This resulted in an RBI of 15.5, an ABI of 62%, and a NNT of 2. A p-value ≤ 0.001 was
reported for each tildrakizumab dose vs. placebo. No associated confidence interval was
provided.
Reich et al.8 conducted three-part, double-blind, parallel, phase 3 RCTs to compare SQ
tildrakizumab to placebo or etanercept in adult patients with mild to moderate plaque psoriasis.
reSURFACE1 was performed between December 2012 to October 2015 at 118 sites in the US,
Australia, Canada, and Japan. In part 1, subjects of both trials were randomized to receive
tildrakizumab (100 mg, 200 mg) or placebo on week 0 and week 4. After evaluation at week 12,
subjects participating in part 2 were re-randomized to receive treatment every 12 weeks, with all
subjects previously on placebo receiving active medication. In part 3, responders and partial
responders to tildrakizumab were re-randomized at week 28 to receive treatment every 12 weeks
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until week 64. Data was dichotomous with subjects reaching PAS1 75 at week 12 or not. All
subjects were followed with a full-analysis-set, which included all randomized subjects who
received at least one dosage of intervention.
A total of 977 subjects were screened and 772 subjects were randomized into
reSURFACE1, with subjects discontinuing part 1 due to the following: 5 side effects, 5 lost to
follow-up, 1 lack of efficacy, 4 physicians decision, 1 progressive disease, 1 pregnancy, 2
protocol violations, and 8 participant withdrawals. Regarding safety and tolerability, the most
common complaints were nasopharyngitis, URTI, and erythema of injection site. Severe side
effects of infections, malignancies, and cardiovascular events were infrequent and similar across
all arms of the study.
Endpoint efficacy was evaluated on week 12 using PASI 75 scores. For reSURFACE1,
the PASI 75 response was 64% with tildrakizumab 100 mg, compared to 6% in the placebo
group. This resulted in an RBI of 9.67, an ABI of 58%, and an NNT of 2. In this trial, the
tildrakizumab arm had a significantly higher proportion of subjects who achieved a PASI 75 at
week 12 than compared to the placebo group with a p<0.0001. The 95% CI from placebo was
51.0-64.1.

TABLE 2: Treatment effects of tildrakizumab for each RCT
Author
Kopp et al.
Papp et al.
Reich et al.

Treatment
IV tildrakizumab 10 mg/kg
SQ tildrakizumab 100 mg
SQ tildrakizumab 100 mg

RBI
0
15.5
9.67

ABI
60%
62%
58%

NNT
2
2
2

P-value
-≤ 0.001
< 0.0001

95% CI
--51.0-64.1
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DISCUSSION
This systematic review is limited as it only evaluates the results from early trials of
tilrakizumab research. In addition, PASI 75 efficacy was evaluated at early endpoints of week 12
and 16 so long-term efficacy and possible tolerance is not demonstrated. The biggest limitations
of Kopp et al.6 phase 1 study was its small number of subjects and suboptimal dosing. The
maximum dosing evaluated was IV tildrakizumab 10 mg because safety and tolerability of the
new drug was a concern. With only 77 participants, and most of them being white males, the
study does not fully evaluate tildrakizumab’s effect on the general population. Of concern, no
confidence internal or p-value was provided, reducing the ability to determine precision of the
provided data. While this does raise some suspicion, the data itself is supportive of even
suboptimal dosage of tildrakizumab 10 mg making a positive effect on psoriasis patients with a
NNT of 2.
Papp et al.7 had a larger sample size of 353 randomized patients. Most of the subjects
were white (82%) and male (76%), raising concern for tildrakizumab’s effect on a more diverse
population. Although a confidence interval was not reported, a statistically significant p-value ≤
0.001 was reported and supports the efficacy of tildrakizumab 100 mg with a NNT of 2. In
general, this study illustrates the dose-dependent efficacy of tildrakizumab and its tolerability.
Reich et al.8 provided a little more diversity in reSURFACE1 with a representation of Asians,
but still lacks gender and more extensive racial inclusion. The reSURFACE trial encompassed a
bigger sample size, provided a statistically significant p-value < 0.0001, and had a relatively
narrow 95% confidence interval compared to placebo. This supports tildrakizumb’s efficacy as
monotherapy.
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In all three studies, re-randomization was done through different parts of the trials and
should be taken into consideration when making comparisons. Direct comparisons of these three
studies cannot easily be made as different modes of administration were used (IV, SQ), different
dosage of medication was used, and efficacy was measured at different time periods (week 12,
week 16). Tildrakizumab’s efficacy was only evaluated after 12-16 weeks of treatment, further
research is needed to determine long term side effects and efficacy, the possibility of tolerance or
diminished effect, and efficacy in genders and ethnicities. Research is also needed to compare
tildrakizumab to leading therapies that are already on the market. Combination therapy with
tildrakizumab and other therapies may also prove to be beneficial to patients. Despite these
differences and limitations all three double-blind, RCTs reported a NNT of 2 and showed a
statistically significant reduction of psoriatic plaques with the use of tildrakizumab.
CONCLUSION
All three studies illustrate that tildrakizumab is effective as monotherapy in adults with
moderate to severe plaque psoriasis. While no new trials have been performed, additional
evaluations of the above trials have been performed. The reSURFACE trials were extended to
evaluate patient tolerance and efficacy after two years, with positive results.9 In addition, a
retrospective analysis of patients with psoriasis of the genitalia reported improvement in their
quality of life and personal relationships after treatment with tildrakizumab.10 Tildrakizumab has
only recently been approved for commercial use, but as it is more widely used in the outpatient
setting, more population inclusive information is likely to be reported. Further research is needed
to directly compare the efficacy of tildrakizumab to other well-established biologics and
therapies. Research regarding efficacy and adjunctive therapies with tilrakizumab is important as
many patients have tried many medications, including biologics and still have refractory

Wiseman, Tildrakizumab and Psoriasis 12
psoriasis. With efficacious results in trials, tildrakizumab may be able to provide long awaited
relief to someone who has been fighting psoriasis for many years. Although there are still
unknowns regarding the medication, tildrakizumab is already proving to be life changing for
several patients.
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